Empagliflozin: all 403 studies that test it
Page 4 of 5. Open to participants first (103), then studies with results posted, then the rest; newest registration first within each.
- Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes MellitusCompletedNCT04665284Phase 4
- Effect of Empagliflozin on Liver Fat in Non-diabetic PatientsCompletedNCT04642261Phase 4
- Combined Active Treatment in Type 2 Diabetes With NASHCompletedNCT04639414Phase 4
- Empagliflozin and Atrial Fibrillation TreatmentStatus unknownNCT04583813Phase 4
- Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)Active, not recruitingNCT04541797Not applicable
- POST-CABGDM: Empagliflozin in Perioperative CABGCompletedNCT04523064Phase 4
- A Pilot Study of Empagliflozin in the Treatment of Acromegalic CardiomyopathyStatus unknownNCT04520646Not applicable
- Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary InterventionsCompletedNCT04497792Phase 4
- Empagliflozin and Cardiac Remodelling in People Without DiabetesCompletedNCT04461041Phase 4
- Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic HyponatremiaCompletedNCT04447911Phase 4
- Pharmacokinetic Drug Interaction Between Teneligliptin and EmpagliflozinCompletedNCT04431141Phase 1
- Pharmacological Reduction of Right Ventricular EnlargementCompletedNCT04345796Phase 3
- REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs PopulationsWithdrawnNCT04243850Phase 4
- Renohemodynamic Effects of Combined empagliflOzin and LosARtanCompletedNCT04238702Phase 4
- A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )Status unknownNCT04221152Phase 3
- Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKDStatus unknownNCT04215445Phase 4
- Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 DiabetesStatus unknownNCT04203927Early Phase 1
- Short Term Effect of Empagliflozin in HypertensionCompletedNCT04203914Phase 4
- Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes MellitusStatus unknownNCT04195243Phase 3
- Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)CompletedNCT04183868Phase 4
- SGLT2 Inhibitors in Glomerular HyperfiltrationWithdrawnNCT04143581Phase 2
- Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory AnginaCompletedNCT04143321Phase 4
- Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 DeficiencyStatus unknownNCT04138251Phase 2
- Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With PrediabetesStatus unknownNCT04131582Phase 3
- Effect of Empagliflozin on Ventricular Repolarization.CompletedNCT04117763Phase 4
- Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon SecretionCompletedNCT04061473Not applicable
- Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and AlbuminuriaStatus unknownNCT04061200Phase 4
- Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart FailureCompletedNCT04049045Phase 2
- A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin ResistanceStatus unknownNCT04018365Phase 3
- Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes MellitusStatus unknownNCT04014192Phase 4
- Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient SettingCompletedNCT03979352Phase 3
- Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)TerminatedNCT03933956Phase 3
- Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in HumansStatus unknownNCT03912909Phase 4
- The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of EmpagliflozinCompletedNCT03895229Phase 1
- Effect of Empagliflozin on Body Composition and KetonesStatus unknownNCT03877406Phase 4
- Drug Interaction Study Between Dorzagliatin and EmpagliflozinCompletedNCT03790787Phase 1
- Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.CompletedNCT03771781Not applicable
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male AdultsCompletedNCT03766724Phase 1
- Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes MellitusCompletedNCT03753087Phase 4
- Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).CompletedNCT03713190Phase 2
- Antidiabetic Drugs for Steatotic Liver DiseaseCompletedNCT03646292Phase 4
- Efficacy and Safety of Empagliflozin in NODATTerminatedNCT03642184Phase 4
- The Effects of Empagliflozin on Arterial Wall CharacteristicsStatus unknownNCT03639545Phase 4
- Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCIStatus unknownNCT03591991Not applicable
- Gemigliptin, Dapagliflozin, Empagliflozin DDI StudyStatus unknownNCT03565458Phase 1
- Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study ProtocolCompletedNCT03560375Phase 4
- EMPA Acute Heart FailureTerminatedNCT03554200Phase 2
- Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and EmpagliflozinCompletedNCT03510000Not applicable
- Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)WithdrawnNCT03504566Phase 4
- Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic EffectsCompletedNCT03485092Phase 4
- The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix InsulinStatus unknownNCT03458715Phase 4
- Empagliflozin Effect on Glucose ToxicityWithdrawnNCT03437330Phase 4
- Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetESStatus unknownNCT03433248Phase 4
- Empagliflozin and Sympathetic Nerve TrafficCompletedNCT03254849Phase 4
- Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With PrediabetesCompletedNCT03227484Phase 2
- Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational DiabetesCompletedNCT03215069Phase 3
- Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery DiseaseCompletedNCT03208465Phase 4
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx StudyCompletedNCT03202667Phase 2/3
- Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-StudyCompletedNCT03200782Not applicable
- Empagliflozin in Heart Failure Patients With Reduced Ejection FractionCompletedNCT03198585Phase 2
- Empaglifozin in Early Diabetic Kidney DiseaseWithdrawnNCT03173963Phase 3
- Empagliflozin in Renal Transplant RecipientsCompletedNCT03157414Phase 4
- SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular RiskCompletedNCT03151343Phase 3
- Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 DiabetesCompletedNCT03132181Phase 2
- Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart FailureCompletedNCT03128528Phase 2
- Impact of Empaglifozine on Cardiac Ectopic FatCompletedNCT03118336Phase 3
- Empagliflozin in Post-Transplantation Diabetes MellitusCompletedNCT03113110Phase 2
- Empagliflozin and Renal Oxygenation in Healthy VolunteersCompletedNCT03093103Phase 2
- EMPRA (EMPagliflozin and RAs in Kidney Disease)CompletedNCT03078101Phase 2
- Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on MetforminTerminatedNCT03060980Phase 3
- Pharmacokinetic Evaluation of EmpagliflozinCompletedNCT03059056Phase 1
- SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)CompletedNCT03050229Phase 4
- Empagliflozin in Heart Failure: Diuretic and Cardio-Renal EffectsCompletedNCT03027960Phase 1
- Empagliflozin vs Metformin in PCOSCompletedNCT03008551Phase 2/3
- Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 DiabetesStatus unknownNCT02998970Phase 4
- Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular EdemaTerminatedNCT02985242Phase 4
- The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 DiabetesStatus unknownNCT02964715Phase 4
- Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 DiabetesCompletedNCT02964572Not applicable
- Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 DiabeticsCompletedNCT02932436Phase 4
- The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 DiabetesCompletedNCT02890745Phase 2
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND StudyCompletedNCT02874807Phase 2/3
- Evaluate the Drug-drugs Interaction Between Lobeglitazone and EmpagliflozinStatus unknownNCT02854748Phase 1
- SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.CompletedNCT02798744Phase 4
- The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 InhibitorsCompletedNCT02792400Not applicable
- Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female VolunteersCompletedNCT02782624Phase 1
- Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE StudyCompletedNCT02729766Phase 2/3
- SGLT2 Inhibition and Left Ventricular MassTerminatedNCT02728453Phase 4
- Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 DiabetesCompletedNCT02686476Not applicable
- Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 DiabetesCompletedNCT02637973Phase 4
- Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium FunctionCompletedNCT02471963Phase 3
- Bioavailability of BI 10773 and Pioglitazone in Healthy Male VolunteersCompletedNCT02276365Phase 1
- Single Rising Oral Doses of BI 10773 in Healthy Male VolunteersCompletedNCT02182453Phase 1
- BI 10773 Administered as Oral Solution to Healthy Male VolunteersCompletedNCT02172274Phase 1
- Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male VolunteersCompletedNCT02172261Phase 1
- Relative Bioavailability BI 10773 and Metformin in Healthy Male VolunteersCompletedNCT02172248Phase 1
- Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy VolunteersCompletedNCT02172235Phase 1
- Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male VolunteersCompletedNCT02172222Phase 1
- Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male VolunteersCompletedNCT02172209Phase 1
- Bioavailability of BI 10773 and Sitagliptin in Healthy Male VolunteersCompletedNCT02172196Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male SubjectsCompletedNCT02172170Phase 1